Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Lucrezia Laterza, Gianluca Ianiro, Iolanda Scoleri, Rosario Landi, Giovanni Bruno, Franco Scaldaferri, Eleonora Gaetani, Mariachiara Campanale & Antonio Gasbarrini. (2015) Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 16:4, pages 607-615.
Read now
Read now
Filippo Cremonini & Anthony Lembo. (2012)
Rifaximin for the treatment of irritable bowel syndrome. Expert Opinion on Pharmacotherapy 13:3, pages 433-440.
Read now
Read now
Veronica Ojetti, Ernesto Cristiano Lauritano, Federico Barbaro, Alessio Migneco, Maria Elena Ainora, Luigi Fontana, Maurizio Gabrielli & Antonio Gasbarrini. (2009) Rifaximin pharmacology and clinical implications. Expert Opinion on Drug Metabolism & Toxicology 5:6, pages 675-682.
Read now
Read now
Dennis D Hedge, Joe D Strain, Jodi R Heins & Debra K Farver. (2008) New advances in the treatment of Clostridium difficile infection (CDI). Therapeutics and Clinical Risk Management 4:5, pages 949-964.
Read now
Read now
Joseph Guiles, Ian Critchley & Xicheng Sun. (2008) New agents for Clostridium difficile-associated disease. Expert Opinion on Investigational Drugs 17:11, pages 1671-1683.
Read now
Read now
Articles from other publishers (80)
Jessica A Ward, Jason Yerke, Mollie Lumpkin, Aanchal Kapoor, Christina C Lindenmeyer & Stephanie Bass. (2023) Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy. World Journal of Hepatology 15:11, pages 1226-1236.
Crossref
Crossref
Jyoti Baranwal, Swastika Singh, Smriti Kushwaha & Archana Jyoti. (2023) Acemannan from Aloe vera Extract: A Catalyst-Free, Approach for the
Access of Imidazole-Fused Nitrogen-Bridgehead Heterocycles. Letters in Organic Chemistry 20:5, pages 446-456.
Crossref
Crossref
Gabriela Piovezani Ramos & Michael Camilleri. (2022) Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea. Digestive Diseases and Sciences 68:5, pages 1677-1690.
Crossref
Crossref
Sofia D. Shaikh, Natalie Sun, Andrew Canakis, William Y. Park & Horst Christian Weber. (2023) Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review. Journal of Clinical Medicine 12:7, pages 2558.
Crossref
Crossref
Kashif Mohd Siddiqui, Sumeet Attri, Massimo Orlando, Filippo Lelli, Valeria Maida & Dominique Damais-Thabut. (2022) Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis. GastroHep 2022, pages 1-13.
Crossref
Crossref
Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka & Fumihito Hirai. (2022) Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites. Medicina 58:9, pages 1276.
Crossref
Crossref
Jawaid Shaw, Lisa Beyers & Jasmohan S. Bajaj. (2022) Inadequate practices for hepatic encephalopathy management in the inpatient setting. Journal of Hospital Medicine 17:S1.
Crossref
Crossref
Zheng Zhang, Qi Yuan, Xiaoxuan Hu, Jinmao Liao & Jia Kuang. (2022) Rifaximin protects SH‐SY5Y neuronal cells from iron overload‐induced cytotoxicity via inhibiting STAT3/NF‐κB signaling. Cell Biology International 46:7, pages 1062-1073.
Crossref
Crossref
Yuanbin Liu & Mingkai Chen. (2022) Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review. Canadian Journal of Gastroenterology and Hepatology 2022, pages 1-12.
Crossref
Crossref
Gauri S Khatri, Christine Kurian, Asha Anand & Paari KA. (2021) Gut Homeostasis; Microbial Cross Talks in Health and Disease Management. Current Research in Nutrition and Food Science Journal 9:3, pages 1017-1045.
Crossref
Crossref
Justin P. Reinert & Kevin Burnham. (2020) Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review. Journal of Pharmacy Practice 34:6, pages 922-933.
Crossref
Crossref
Dattatray B. Yedage & Dattatray V. Patil. (2021) Deep Eutectic Solvent‐Mediated Regioselective Synthesis of Imidazoheterocycles. Macromolecular Symposia 400:1, pages 2100089.
Crossref
Crossref
Tomasz Wollny, Tamara Daniluk, Ewelina Piktel, Urszula Wnorowska, Anna Bukłaha, Katarzyna Głuszek, Bonita Durnaś & Robert Bucki. (2021) Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome. Pathogens 10:12, pages 1545.
Crossref
Crossref
Ryunosuke Noda, Giyoung Kwoun, Noriko Matsunaga, Takahiro Yoshikawa, Lisa Uchida & Takamoto Ohse. (2021) Rifaximin prevented the recurrence of hepatic encephalopathy in a hemodialysis patient ‒ A case reportリファキシミンにより肝性脳症の再発を予防できた血液透析患者の1例. Nihon Toseki Igakkai Zasshi 54:11, pages 591-596.
Crossref
Crossref
Atinderpal Kaur & Shweta Dang. 2021. Nanocarriers for the Delivery of Combination Drugs. Nanocarriers for the Delivery of Combination Drugs
337
392
.
Zaid S. Ardalan & Miles P. Sparrow. (2020) A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis. Frontiers in Medicine 6.
Crossref
Crossref
Mitsuhiko Shibasaki, Takeshi Hatanaka, Yasushi Shimada, Tamon Nagashima, Masashi Namikawa, Shuichi Saito, Kenichi Hosonuma, Atsushi Naganuma, Daichi Takizawa, Hirotaka Arai, Takashi Kosone, Hitoshi Takagi, Ken Sato, Satoru Kakizaki & Toshio Uraoka. (2020) Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathy日本人肝硬変患者における肝性脳症へのリファキシミンの有効性と安全性の検討. Kanzo 61:1, pages 1-10.
Crossref
Crossref
Muhammad Miftahussurur, Hafeza Aftab, Pradeep Krishna Shrestha, Rabi Prakash Sharma, Phawinee Subsomwong, Langgeng Agung Waskito, Dalla Doohan, Kartika Afrida Fauzia & Yoshio Yamaoka. (2019) Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrobial Resistance & Infection Control 8:1.
Crossref
Crossref
Bjørn Stæhr Madsen, Jonel Trebicka, Maja Thiele, Mads Israelsen, Manimozhiyan Arumugan, Troels Havelund & Aleksander Krag. (2018) Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. Trials 19:1.
Crossref
Crossref
Fátima Higuera-de-la-Tijera, Alfredo I. Servín-Caamaño, Francisco Salas-Gordillo, José L. Pérez-Hernández, Juan M. Abdo-Francis, Jaime Camacho-Aguilera, Sai N. Alla & Fiacro Jiménez-Ponce. (2018) Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-10.
Crossref
Crossref
Kazuyuki Suzuki, Ryujin Endo, Yasuhiro Takikawa, Fuminori Moriyasu, Yutaka Aoyagi, Hisataka Moriwaki, Shuji Terai, Isao Sakaida, Yoshiyuki Sakai, Shuhei Nishiguchi, Toru Ishikawa, Hitoshi Takagi, Atsushi Naganuma, Takuya Genda, Takafumi Ichida, Koichi Takaguchi, Katsuhiko Miyazawa & Kiwamu Okita. (2018) Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial. Hepatology Research 48:6, pages 411-423.
Crossref
Crossref
Nicola Principi, Rita Cozzali, Edoardo Farinelli, Andrea Brusaferro & Susanna Esposito. (2018) Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. Journal of Infection 76:2, pages 111-120.
Crossref
Crossref
P.C. Barko, M.A. McMichael, K.S. Swanson & D.A. Williams. (2018) The Gastrointestinal Microbiome: A Review. Journal of Veterinary Internal Medicine 32:1, pages 9-25.
Crossref
Crossref
Orla Craig. (2018) New therapies in Irritable Bowel Syndrome. Current Opinion in Gastroenterology 34:1, pages 50-56.
Crossref
Crossref
Marinko Marušić, Rosana Troskot Perić & Nikolina Tolj Karaula. 2018. Gastrointestinal Complications of Diabetes. Gastrointestinal Complications of Diabetes
191
201
.
Mercedes Ramas, Maria G. Donday, Adrian G. McNicholl & Javier P. Gisbert. (2017) Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterología y Hepatología 40:10, pages 658-662.
Crossref
Crossref
Mercedes Ramas, Maria G. Donday, Adrian G. McNicholl & Javier P. Gisbert. (2017) Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterología y Hepatología (English Edition) 40:10, pages 658-662.
Crossref
Crossref
S. H. Kang, Y. B. Lee, J.-H. Lee, J. Y. Nam, Y. Chang, H. Cho, J.-J. Yoo, Y. Y. Cho, E. J. Cho, S. J. Yu, M. Y. Kim, Y. J. Kim, S. K. Baik & J.-H. Yoon. (2017) Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 46:9, pages 845-855.
Crossref
Crossref
Faisal Kamal, Muhammad Ali Khan, Zubair Khan, George Cholankeril, Tariq A. Hammad, Wade M. Lee, Aijaz Ahmed, Bradford Waters, Colin W. Howden, Satheesh Nair & Sanjaya K. Satapathy. (2017) Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis. European Journal of Gastroenterology & Hepatology 29:10, pages 1109-1117.
Crossref
Crossref
Qin Xiang Ng, Collin Yih Xian Ho, Dongju Shin, Nandini Venkatanarayanan & Hwei Wuen Chan. (2017) A meta-analysis of the use of rifaximin to prevent travellers’ diarrhoea. Journal of Travel Medicine 24:5.
Crossref
Crossref
Fatima Tufail, Swastika Singh, Mohammad Saquib, Jyoti Tiwari, Jaya Singh & Jagdamba Singh. (2017) Catalyst-Free, Glycerol-Assisted Facile Approach to Imidazole-Fused Nitrogen-Bridgehead Heterocycles. ChemistrySelect 2:21, pages 6082-6089.
Crossref
Crossref
Samuel L. M. ArnoldRyan ChoiMatthew A. HulversonDeborah A. Schaefer, Sumiti Vinayak, Rama S. R. VidadalaMolly C. McCloskeyGrant R. WhitmanWenlin HuangLynn K. BarrettKayode K. OjoErkang FanDustin J. Maly, Michael W. Riggs, Boris Striepen & Wesley C. Van Voorhis. (2017) Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection. The Journal of Infectious Diseases 216:1, pages 55-63.
Crossref
Crossref
Joanna Oświęcimska, Agnieszka Szymlak, Wojciech Roczniak, Katarzyna Girczys-Połedniok & Jarosław Kwiecień. (2017) New insights into the pathogenesis and treatment of irritable bowel syndrome. Advances in Medical Sciences 62:1, pages 17-30.
Crossref
Crossref
Kamesh Gupta, Harparam Singh Ghuman & Shivani Vijay Handa. (2017) Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clinical Medicine Insights: Gastroenterology 10, pages 117955221772890.
Crossref
Crossref
Anthony Lembo, Mark Pimentel, Satish S. Rao, Philip Schoenfeld, Brooks Cash, Leonard B. Weinstock, Craig Paterson, Enoch Bortey & William P. Forbes. (2016) Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 151:6, pages 1113-1121.
Crossref
Crossref
Artur Dembiński, Zygmunt Warzecha, Piotr Ceranowicz, Marcin Dembiński, Jakub Cieszkowski, Tomasz Gosiewski, Małgorzata Bulanda, Beata Kuśnierz-Cabala, Krystyna Gałązka & Peter Christopher Konturek. (2016)
Synergic Interaction of Rifaximin and Mutaflor (
Escherichia coli
Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats
. Gastroenterology Research and Practice 2016, pages 1-11.
Crossref
Crossref
M. Pimentel. (2016) Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Alimentary Pharmacology & Therapeutics 43, pages 37-49.
Crossref
Crossref
J.M. Remes Troche. (2016) Reflections on antibiotic resistance and what to do about it. Revista de Gastroenterología de México (English Edition) 81:1, pages 1-2.
Crossref
Crossref
J.M. Remes Troche. (2016) Reflexiones sobre la resistencia a antibióticos y qué hacer al respecto. Revista de Gastroenterología de México 81:1, pages 1-2.
Crossref
Crossref
Martin Bitzan & Anne-Laure Lapeyraque. 2016. Pediatric Kidney Disease. Pediatric Kidney Disease
653
731
.
Hiroshi Fukui. (2015) Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World Journal of Hepatology 7:3, pages 425.
Crossref
Crossref
Andy Liu. (2015) Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World Journal of Hepatology 7:29, pages 2871.
Crossref
Crossref
P.S. Mantry, A. Mehta & R. Graydon. (2014) Efficacy and Tolerability of Rifaximin in Combination With Lactulose in End-stage Liver Disease Patients With MELD Greater Than 20: A Single Center Experience. Transplantation Proceedings 46:10, pages 3481-3486.
Crossref
Crossref
Max Schmulson, María Victoria Bielsa, Ramón Carmona-Sánchez, Angélica Hernández, Aurelio López-Colombo, Yolanda López Vidal, Mario Peláez-Luna, José María Remes-Troche, José Luis Tamayo & Miguel Angel Valdovinos. (2014) Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review. Revista de Gastroenterología de México (English Edition) 79:2, pages 96-134.
Crossref
Crossref
M. Schmulson, M.V. Bielsa, R. Carmona-Sánchez, A. Hernández, A. López-Colombo, Y. López Vidal, M. Peláez-Luna, J.M. Remes-Troche, J.L. Tamayo & M.A. Valdovinos. (2014) Microbiota, infecciones gastrointestinales, inflamación de bajo grado y antibioticoterapia en el síndrome de intestino irritable. Una revisión basada en evidencias. Revista de Gastroenterología de México 79:2, pages 96-134.
Crossref
Crossref
Barjesh Chander Sharma, Praveen Sharma, Manish Kumar Lunia, Siddharth Srivastava, Rohit Goyal & S K Sarin. (2013) A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. American Journal of Gastroenterology 108:9, pages 1458-1463.
Crossref
Crossref
Caroline Schrodt, Erin E. McHugh, Mary Ann Gawinowicz, Herbert L. DuPont & Eric L. Brown. (2013) Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis. PLoS ONE 8:7, pages e68550.
Crossref
Crossref
Bjørn S. Madsen, Troels Havelund & Aleksander Krag. (2013) Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers. Advances in Therapy 30:7, pages 659-670.
Crossref
Crossref
Jiannis Vlachogiannakos, Nikos Viazis, Panagiota Vasianopoulou, Irene Vafiadis, Dimitrios G Karamanolis & Spiros D Ladas. (2013) Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. Journal of Gastroenterology and Hepatology 28:3, pages 450-455.
Crossref
Crossref
Michael Melter & Stephan Buderus. 2013. Pädiatrische Gastroenterologie, Hepatologie und Ernährung. Pädiatrische Gastroenterologie, Hepatologie und Ernährung
777
792
.
Hsin‐Yun Sun, Marilyn Wagener, Thomas V. Cacciarelli & Nina Singh. (2012) Impact of rifaximin use for hepatic encephalopathy on the risk of early post‐transplant infections in liver transplant recipients. Clinical Transplantation 26:6, pages 849-852.
Crossref
Crossref
Sang-Pil Yun, Han Gyung Seon, Chang Soo Ok, Kwang Ho Yoo, Min Kyung Kang, Won Hee Kim, Chang Il Kwon, Kwang Hyun Ko, Seong Gyu Hwang, Pil Won Park & Sung Pyo Hong. (2012) Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori. Gut and Liver 6:4, pages 452-456.
Crossref
Crossref
Amit H. Sachdev & Mark Pimentel. (2012) Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence. Current Gastroenterology Reports 14:5, pages 439-445.
Crossref
Crossref
Vandana Khungar & Fred Poordad. (2012) Hepatic Encephalopathy. Clinics in Liver Disease 16:2, pages 301-320.
Crossref
Crossref
Vandana Khungar & Fred Poordad. (2012) Management of Overt Hepatic Encephalopathy. Clinics in Liver Disease 16:1, pages 73-89.
Crossref
Crossref
Z. Poh & P. E. J. Chang. (2012) A Current Review of the Diagnostic and Treatment Strategies of Hepatic Encephalopathy. International Journal of Hepatology 2012, pages 1-10.
Crossref
Crossref
K. W. Garey, S. S. Ghantoji, D. N. Shah, M. Habib, V. Arora, Z.-D. Jiang & H. L. DuPont. (2011) A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 66:12, pages 2850-2855.
Crossref
Crossref
Mark Pimentel, Walter Morales, Kathleen Chua, Gillian Barlow, Stacy Weitsman, Gene Kim, Meridythe M. Amichai, Venkata Pokkunuri, Emily Rook, Ruchi Mathur & Zachary Marsh. (2011) Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects. Digestive Diseases and Sciences 56:7, pages 2067-2072.
Crossref
Crossref
Mark Pimentel, Anthony Lembo, William D. Chey, Salam Zakko, Yehuda Ringel, Jing Yu, Shadreck M. Mareya, Audrey L. Shaw, Enoch Bortey & William P. Forbes. (2011) Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. New England Journal of Medicine 364:1, pages 22-32.
Crossref
Crossref
Andrea Mencarelli, Marco Migliorati, Miriam Barbanti, Sabrina Cipriani, Giuseppe Palladino, Eleonora Distrutti, Barbara Renga & Stefano Fiorucci. (2010) Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochemical Pharmacology 80:11, pages 1700-1707.
Crossref
Crossref
Nathan M. Bass, Kevin D. Mullen, Arun Sanyal, Fred Poordad, Guy Neff, Carroll B. Leevy, Samuel Sigal, Muhammad Y. Sheikh, Kimberly Beavers, Todd Frederick, Lewis Teperman, Donald Hillebrand, Shirley Huang, Kunal Merchant, Audrey Shaw, Enoch Bortey & William P. Forbes. (2010) Rifaximin Treatment in Hepatic Encephalopathy. New England Journal of Medicine 362:12, pages 1071-1081.
Crossref
Crossref
Meghan K. Harris, Debra Elliott, Robert N. Schwendimann, Alireza Minagar & Stephen L. Jaffe. (2010) Neurologic Presentations of Hepatic Disease. Neurologic Clinics 28:1, pages 89-105.
Crossref
Crossref
Francesco. Parenti & Giancarlo. Lancini. 2010. Antibiotic and Chemotherapy. Antibiotic and Chemotherapy
326
333
.
Miguel Salazar, Kevin W. Garey, Zhi-Dong Jiang, Thanh Dao-Tran & Herbert DuPont. (2009) Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharmacy World & Science 31:5, pages 565-571.
Crossref
Crossref
Indi Trehan, Robert J Shulman, Ching-Nan Ou, Kenneth Maleta & Mark J Manary. (2009) A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Nonabsorbable Antibiotic, in the Treatment of Tropical Enteropathy. The American Journal of Gastroenterology 104:9, pages 2326-2333.
Crossref
Crossref
Behzad Elahi, Shekoufeh Nikfar, Saeed Derakhshani, Mohammad Vafaie & Mohammad Abdollahi. (2009) Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials. Open Medicine 4:2, pages 164-170.
Crossref
Crossref
Darego O Maclayton & Angie Eaton-Maxwell. (2008) Rifaximin for Treatment of Hepatic Encephalopathy. Annals of Pharmacotherapy 43:1, pages 77-84.
Crossref
Crossref
Kevin W. Garey, Zhi-Dong Jiang, Angelle Bellard & Herbert L. DuPont. (2009) Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study. Journal of Clinical Gastroenterology 43:1, pages 91-92.
Crossref
Crossref
D Bobak, L M Arfons, R J Creger & H M Lazarus. (2008) Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?. Bone Marrow Transplantation 42:11, pages 705-713.
Crossref
Crossref
Tomasz Z Jodlowski, Sum Lam & Charles Ft AshbyJrJr. (2008) Emerging Therapies for the Treatment of Helicobacter pylori Infections. Annals of Pharmacotherapy 42:11, pages 1621-1639.
Crossref
Crossref
Kevin W Garey, Miguel Salazar, Dhara Shah, Richard Rodrigue & Herbert L DuPont. (2008) Rifamycin Antibiotics for Treatment of Clostridium difficile–Associated Diarrhea. Annals of Pharmacotherapy 42:6, pages 827-835.
Crossref
Crossref
David A. Bobak. (2008) Clinical trials report. Current Infectious Disease Reports 10:2, pages 89-91.
Crossref
Crossref
Xicheng Sun, Joseph Guiles & Nebojsa Janjic. 2008.
269
279
.
Janet Yang, Hyo-Rang Lee, Kimberly Low, Soumya Chatterjee & Mark Pimentel. (2007) Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. Digestive Diseases and Sciences 53:1, pages 169-174.
Crossref
Crossref
Robert C. OwensJrJr, August J. Valenti & Mark H. Wilcox. 2007. Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures
183
218
.
Robert C. Owens & August J. Valenti. (2007) Clostridium difficile-Associated Disease in the New Millennium. Infectious Diseases in Clinical Practice 15:5, pages 299-315.
Crossref
Crossref
Cyrus P. Tamboli. (2007) Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America 87:3, pages 697-725.
Crossref
Crossref
. (2007) Treatment of Clostridium difficile–Associated Disease (CDAD). Obstetrics & Gynecology 109:4, pages 993-995.
Crossref
Crossref
Daniel M. Musher, Nancy Logan, Vaibhav Mehendiratta, Nicolas A. Melgarejo, Sagar Garud & Richard J. Hamill. (2007) Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. Journal of Antimicrobial Chemotherapy 59:4, pages 705-710.
Crossref
Crossref
Tomasz Z Jodlowski, Richard Oehler, Linda W Kam & Igor Melnychuk. (2016) Emerging Therapies in the Treatment of Clostridium difficile–Associated Disease. Annals of Pharmacotherapy 40:12, pages 2164-2169.
Crossref
Crossref